Dutch Bioscience firm DSM Firmenich told CNBC Wednesday that it is exploring nutritional supplements to complement and compensate for some of the impacts of the weight loss drugs.
"If you go to weight loss and you're successful, you move to the health, nutrition, lifestyle counter, because you basically want to continue what you have. There we come into play," de Vreeze told CNBC's "Squawk Box Europe."The weight-loss injections, which rely on a group of drugs called GLP-1 receptor agonists , which work by imitating a naturally occurring gut hormone that helps regulate appetite in the brain.
"That said, consumers could also eat more weight management foods as they strive to eat healthier and substitute such products over more indulgent snacking alternatives," he added. "We think it is too early for investors to take definitive positioning outside of healthcare stocks on the impact of GLP-1 drugs, and the range of potential scenarios is very wide," Barclays analysts wrote.Asked whether rising demand for nutritional products was being reflected in his company's share price, de Vreeze acknowledged it was "too early" to say.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: NBCNewYork - 🏆 270. / 63 Read more »